Cargando…
The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
PURPOSE: To date, aclidinium pharmacokinetic (PK) studies have focused on Caucasian populations, and no data are available for Chinese populations. We aimed to characterize the PK and safety profile of aclidinium and its metabolites (LAS34823 and LAS34850) following single and multiple (twice-daily;...
Autores principales: | Li, Weimin, Daoud, Sami Z, Trivedi, Roopa, Lukka, Pradeep B, Jimenez, Eulalia, Molins, Eduard, Stewart, Catherine, Bharali, Pranob, Garcia-Gil, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691958/ https://www.ncbi.nlm.nih.gov/pubmed/38046981 http://dx.doi.org/10.2147/COPD.S434588 |
Ejemplares similares
-
Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016) -
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022) -
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022) -
Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
por: Sims, Michael W, et al.
Publicado: (2011) -
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Zhong, Jun, et al.
Publicado: (2014)